Cancer of the Lung And SeneScencE - Prospective Cohort 1

Geriatric assessment allows oncologists to stratify older cancer patients into risk categories (fit, vulnerable and frail) but few patients benefit from it. Yet, they do not evaluate physiological reserves when oncologists are in dire need of quantitative tools accounting for age-related changes. This decade has witnessed the remarkable power of multiple tools (epigenetics, telomere integrity, cellular and immunosenescence) to estimate an individual's age. These tools hold the potential for routine implementation in the clinic and to be combined with existing tests. The main objective is to identify and assess the predictive value of ageing and senescence biomarkers (methylome, telomeres, inflammageing) and senescent cells in tissues to improve to improve prognosis assessment in older patients with locally or locally-advanced Non-Small Cell Lung Cancer (NSCLC).

The ambition of this study is to refine the prognosis assessment and optimize decision-making process, better anticipate adverse-events and unplanned hospitalization and better manage and care high risk patients of early death, unplanned hospitalization, major complication or toxicities and altered quality of life.

• Mortality (all-cause) and cause-specific [Срок оценки: Month 12 and Month 60 post surgery]
• Surgical Complications [Срок оценки: Month 3 and Month 6 post surgery]
• Major Toxicities [Срок оценки: Month 3 and Month 6 post surgery]
• Quality of Life Core 30 [Срок оценки: Month 6 and Month 12 post surgery.]
• Quality of Life Lung Cancer 13 [Срок оценки: Month 6 and Month 12 post surgery]
• Quality of Life Elderly 14 [Срок оценки: Month 6 and Month 12 post surgery]
• Disease-free survival [Срок оценки: Month 3, Month 12 and Month 60 post surgery]
• Geriatric Parameters G-CODE [Срок оценки: Month 3 and Month 6 post surgery]
• Geriatric Parameters Hand grip [Срок оценки: Month 3 and Month 6 post surgery]